A5005725388- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Immune cells in cancer
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
- Genetic factors in colorectal cancer
- MicroRNA in disease regulation
- Adenosine and Purinergic Signaling
- PARP inhibition in cancer therapy
- Hepatocellular Carcinoma Treatment and Prognosis
Zhongshan Hospital
2022-2024
Shanghai Medical College of Fudan University
2022-2024
Fudan University
2022-2024
<p>Supplementary materials and methods, Supplementary Figures figure legends, Tables</p>
<div>Abstract<p>Anti–PD-L1–based combination immunotherapy has become the first-line treatment for unresectable hepatocellular carcinoma (HCC). However, objective response rate is lower than 40%, highlighting need to identify mechanisms of tolerance immune checkpoint inhibitors and accurate biomarkers response. In this study, we used next-generation sequencing analyze HCC samples from 10 patients receiving anti–PD-L1 therapy. Activation renin–angiotensin system was elevated in...
Abstract Anti-PD-L1-based combination immunotherapy has become the first-line treatment for unresectable hepatocellular carcinoma (HCC). However, objective response rate is lower than 40%, highlighting need to identify mechanisms of tolerance immune checkpoint inhibitors and accurate biomarkers response. Here, we employed next-generation sequencing analyze HCC samples from 10 patients receiving anti-PD-L1 therapy. Activation renin-angiotensin system was elevated in nonresponders compared...